methyl 2-(4-bromobutoxy)benzoate | 158236-22-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-bromobutoxy)benzoate
• CAS: 158236-22-7
• 化学式: C₁₂H₁₅BrO₃
• 分子量: 287.153
• InChiKey: PPHMFLQCFQMVOS-UHFFFAOYSA-N

物化性质

• 沸点：
  366.3±22.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-bromobutoxy)benzoate 在 potassium carbonate 、 sodium iodide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 12.0h， 生成 2-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-N-methylbenzamide
  参考文献：
  名称：

  一系列苯甲酰胺作为潜在的多受体抗精神病药的合成，构效关系和生物学评估。

  摘要：

  在本研究中，合成了一系列具有强力多巴胺D2、5-羟色胺5-HT1A和5-HT2A受体特性的苯甲酰胺，并将其评估为潜在的抗精神病药。其中，持有3-（4-（4-（4-（6-氟苯并[d]异恶唑-3-基）-哌啶-1-基）丁氧基] -N-甲基苯甲酰胺（21）及其氟代类似物（22）最佳的药理结合特征。它们不仅表现出对D2、5-HT1A和5-HT2A受体的有效活性，而且对5-HT2C，H1受体和hERG通道的活性低，提示诱导体重增加和QT延长的可能性低。在动物模型中，化合物21和22降低了苯环利定诱导的机能亢进，且僵直诱导的阈值较高。因此，它为进一步的临床前研究提供了潜在的候选者。

  DOI：

  10.1016/j.bmcl.2016.04.087
• 作为产物：
  描述：

  1,4-二溴丁烷 、 水杨酸甲酯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 4.0h， 以89%的产率得到methyl 2-(4-bromobutoxy)benzoate
  参考文献：
  名称：

  一系列苯甲酰胺作为潜在的多受体抗精神病药的合成，构效关系和生物学评估。

  摘要：

  在本研究中，合成了一系列具有强力多巴胺D2、5-羟色胺5-HT1A和5-HT2A受体特性的苯甲酰胺，并将其评估为潜在的抗精神病药。其中，持有3-（4-（4-（4-（6-氟苯并[d]异恶唑-3-基）-哌啶-1-基）丁氧基] -N-甲基苯甲酰胺（21）及其氟代类似物（22）最佳的药理结合特征。它们不仅表现出对D2、5-HT1A和5-HT2A受体的有效活性，而且对5-HT2C，H1受体和hERG通道的活性低，提示诱导体重增加和QT延长的可能性低。在动物模型中，化合物21和22降低了苯环利定诱导的机能亢进，且僵直诱导的阈值较高。因此，它为进一步的临床前研究提供了潜在的候选者。

  DOI：

  10.1016/j.bmcl.2016.04.087

文献信息

• Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines
  作者：Valeria Sorrenti、Valeria Pittalà、Giuseppe Romeo、Emanuele Amata、Maria Dichiara、Agostino Marrazzo、Rita Turnaturi、Orazio Prezzavento、Ignazio Barbagallo、Luca Vanella、Antonio Rescifina、Giuseppe Floresta、Daniele Tibullo、Francesco Di Raimondo、Sebastiano Intagliata、Loredana Salerno

  DOI：10.1016/j.ejmech.2018.09.048

  日期：2018.10

  Heme oxygenase-1 (HO-1) is a cytoprotective enzyme and a survival-enhancing factor in a number of cancers. Chronic myeloid leukemia (CML) is a blood cancer caused by pathological kinase activity of the BCR-ABL protein, currently treated with tyrosine kinase inhibitors (TKIs) such as Imatinib (IM). However, resistance to TKIs persists in a number of patients and HO-1 overexpression has been linked with the induction of chemoresistance in CML. With this in mind, in this study, we designed and synthesized the first series of hybrid compounds obtained by combining the structures of IM, as BCR-ABL inhibitor, with imidazole-based HO-1 inhibitors. We found that many hybrids were able to inhibit the enzymatic activity of both targets and to reduce the viability of CML-IM resistant cells, showing that a single molecular entity may reduce the resistance phenomenon. (C) 2018 Elsevier Masson SAS. All rights reserved.
• Design and Synthesis of Systemically Active Metabotropic Glutamate Subtype-2 and -3 (mGlu_2/3) Receptor Positive Allosteric Modulators (PAMs): Pharmacological Characterization and Assessment in a Rat Model of Cocaine Dependence
  作者：Raveendra-Panickar Dhanya、Douglas J. Sheffler、Russell Dahl、Melinda Davis、Pooi San Lee、Li Yang、Hilary Highfield Nickols、Hyekyung P. Cho、Layton H. Smith、Manoranjan S. D’Souza、P. Jeffrey Conn、Andre Der-Avakian、Athina Markou、Nicholas D. P. Cosford

  DOI：10.1021/jm5000563

  日期：2014.5.22

  As part of our ongoing small-molecule metabotropic glutamate (mGlu) receptor positive allosteric modulator (PAM) research, we performed structure activity relationship (SAR) studies around a series of group II mGlu PAMs. Initial analogues exhibited weak activity as mGlu(2) receptor PAMs and no activity at mGlu(3). Compound optimization led to the identification of potent mGlu(2/3) selective PAMs with no in vitro activity at mGlu(1,4-8) or 45 other CNS receptors. In vitro pharmacological characterization of representative compound 44 indicated agonist-PAM activity toward mGlu(2) and PAM activity at mGlu(3). The most potent mGlu(2/3) PAMs were characterized in assays predictive of ADME/T and pharmacokinetic (PK) properties, allowing the discovery of systemically active mGlu(2/3) PAMs. On the basis of its overall profile, compound 74 was selected for behavioral studies and was shown to dose-dependently decrease cocaine self-administration in rats after intraperitoneal administration. These mGlu(2/3) receptor PAMs have significant potential as small molecule tools for investigating group II mGlu pharmacology.
• Synthesis of Novel Phthalocyanine−Tetrathiafulvalene Hybrids; Intramolecular Fluorescence Quenching Related to Molecular Geometry
  作者：Christopher Farren、Christian A. Christensen、Simon FitzGerald、Martin R. Bryce、Andrew Beeby

  DOI：10.1021/jo020340y

  日期：2002.12.1

  A number of silicon phthalocyanine bis-esters have been synthesized and characterized, with axial ligands containing one or more tetrathiafulvalene groups. Variations in the substitution positions around a central aromatic "hinge" within the ligands lead to different molecular geometries, and the fluorescence of the macrocyclic core is subsequently quenched to varying degrees by the electron-rich tetrathiafulvalene moiety, the magnitude of this effect being dependent upon both the relative separation of the two units and the flexibility of the linking group. Pc derivative 24, with a highly flexible linker group, and pc derivative 28, with a dendritic axial ligand, have the intensity of the macrocycle emission reduced by 99% and 96%, respectively, relative to a similar silicon pc reference compound lacking the TTF moieties. Molecular modeling studies of a series of such hybrids allow the degree of this fluorescence quenching to be related to the intramolecular spacing. Additionally, the potential for rapid electrochemical switching of the phthalocyanine fluorescence by oxidation of the appended tetrathiafulvalene units is explored.
• Synthesis, structure–activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics
  作者：Feipu Yang、Xiangrui Jiang、Jianfeng Li、Yu Wang、Yongjian Liu、Minghao Bi、Chunhui Wu、Qingjie Zhao、Weiming Chen、Jingjing Yin、Jian Zhang、Yuanchao Xie、Tianwen Hu、Mingshuo Xu、Shuang Guo、Zhen Wang、Yang He、Jingshan Shen

  DOI：10.1016/j.bmcl.2016.04.087

  日期：2016.7

  study, a series of benzamides, endowed with potent dopamine D2, serotonin 5-HT1A and 5-HT2A receptors properties, was synthesized and evaluated as potential antipsychotics. Among them, 3-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy)-N-methylbenzamide (21) and its fluoro-substituted analogue (22) held the best pharmacological binding profiles. They not only presented potent activities for

  在本研究中，合成了一系列具有强力多巴胺D2、5-羟色胺5-HT1A和5-HT2A受体特性的苯甲酰胺，并将其评估为潜在的抗精神病药。其中，持有3-（4-（4-（4-（6-氟苯并[d]异恶唑-3-基）-哌啶-1-基）丁氧基] -N-甲基苯甲酰胺（21）及其氟代类似物（22）最佳的药理结合特征。它们不仅表现出对D2、5-HT1A和5-HT2A受体的有效活性，而且对5-HT2C，H1受体和hERG通道的活性低，提示诱导体重增加和QT延长的可能性低。在动物模型中，化合物21和22降低了苯环利定诱导的机能亢进，且僵直诱导的阈值较高。因此，它为进一步的临床前研究提供了潜在的候选者。